CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06904066
Title field or adapter rule: {'original_value': 'A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies', 'source_field': 'protocolSection.identificationModule.officialTitle'}
Ingested At: 2026-10-31T23:27:29.127421+00:00
Published At: 2026-10-30T00:00:00+00:00
Record Updated At: 2026-10-30
Source Retrieved At: 2026-10-31T22:18:11.341859+00:00
Timestamp Basis: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter
Date limitation: ClinicalTrials.gov API/RSS response retrieval timestamp recorded by Dossier adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions: ["Malignancy, Hematologic", "Neoplasms, Hematologic", "Neoplasms, Hematopoietic", "Blood Cancer", "Hematological Neoplasms", "Hematopoietic Malignancies", "Dysmyelopoietic Syndromes", "Hematopoetic Myelodysplasia", "Myeloid Leukemia, Acute", "Nonlymphoblastic Leukemia, Acute", "Leukemia, Lymphocytic, Acute"]
protocolSection.statusModule.lastUpdatePostDateStruct: {"date": "2026-10-30", "type": "ACTUAL"}
protocolSection.identificationModule.nctId: "NCT06904066"
protocolSection.identificationModule.officialTitle: "A Phase I Study of Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, and Other Hematologic Malignancies"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct: null

Study condition terms

Interventions recorded in this study

{'armGroupLabels': ['1/Experimental: No allo-HSCT', '2/Experimental: prior allo-HSCT'], 'description': 'Aldesleukin 600,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 10 doses).', 'name': 'aldesleukin', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['1/Experimental: No allo-HSCT', '2/Experimental: prior allo-HSCT'], 'description': '300 mg/m\\^2 IV infusion over 30 minutes. Daily x 3 doses on days -5, -4, -3.', 'name': 'cyclophosphamide', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['1/Experimental: No allo-HSCT', '2/Experimental: prior allo-HSCT'], 'description': '30 mg/m\\^2 IV infusion over 30 minutes administered immediately following cyclophosphamide on day -5, -4, -3. Participants with renal dysfunction receive a lower dose of fludarabine.', 'name': 'fludarabine phosphate', 'type': 'DRUG'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['1/Experimental: No allo-HSCT', '2/Experimental: prior allo-HSCT'], 'description': 'Up to 1.5x10\\^11 total cells for non-transplant subjects. 1x10\\^10 total cells for post-alloHSCT subjects.', 'name': 'Individual Patient TCR-Transduced PBL', 'type': 'BIOLOGICAL'} (protocolSection.armsInterventionsModule.interventions[])
{'armGroupLabels': ['1/Experimental: No allo-HSCT', '2/Experimental: prior allo-HSCT'], 'description': 'TSO500 sequencing panel performed in the NCI Laboratory of Pathology to detect TP53 or RAS mutations', 'name': 'TruSight Oncology (TSO) 500', 'type': 'DEVICE'} (protocolSection.armsInterventionsModule.interventions[])

An intervention appearing in a study record does not establish an effect or an approved use.

Drug names recorded in this source

A recorded drug name is not by itself an indication or a condition-specific relationship.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.